MA47516A - Composition pharmaceutique - Google Patents

Composition pharmaceutique

Info

Publication number: MA47516A
Authority: MA; Morocco
Prior art keywords: pharmaceutical composition; pharmaceutical; composition
Prior art date: 2017-02-15

Application number

MA047516A

Other languages

English (en)

Inventor

Shinji Okada

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-15

Filing date

2018-02-14

Publication date

2021-03-31

2018-02-14 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2021-03-31 Publication of MA47516A publication Critical patent/MA47516A/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MA047516A 2017-02-15 2018-02-14 Composition pharmaceutique MA47516A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2017026203		2017-02-15

Publications (1)

Publication Number	Publication Date
MA47516A true MA47516A (fr)	2021-03-31

Family

ID=63169269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047516A MA47516A (fr)	2017-02-15	2018-02-14	Composition pharmaceutique

Country Status (20)

Country	Link
US (2)	US11110062B2 (fr)
EP (1)	EP3583943B1 (fr)
JP (1)	JP6771594B2 (fr)
KR (2)	KR20210135354A (fr)
CN (2)	CN117137915A (fr)
AU (1)	AU2018222163C1 (fr)
CA (1)	CA3053739C (fr)
DK (1)	DK3583943T3 (fr)
ES (1)	ES2991062T3 (fr)
FI (1)	FI3583943T3 (fr)
HU (1)	HUE068810T2 (fr)
MA (1)	MA47516A (fr)
MX (2)	MX2021007061A (fr)
MY (1)	MY194278A (fr)
PH (1)	PH12019501873A1 (fr)
PL (1)	PL3583943T3 (fr)
PT (1)	PT3583943T (fr)
SG (1)	SG11201907433TA (fr)
TW (1)	TWI702951B (fr)
WO (1)	WO2018151177A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3583943T3 (da)	2017-02-15	2024-10-14	Taiho Pharmaceutical Co Ltd	Farmaceutisk sammensætning
EP3682882A4 (fr)	2017-09-08	2021-06-02	Taiho Pharmaceutical Co., Ltd.	Agent antitumoral et potentialisateur d'effet antitumoral
KR20210060465A (ko)	2018-09-18	2021-05-26	다이호야쿠힌고교 가부시키가이샤	아실티오우레아 화합물과 아비라테론의 병용 요법
TWI872203B (zh) *	2020-02-14	2025-02-11	日商大鵬藥品工業股份有限公司	醯基硫脲化合物的製造方法
KR20220128310A (ko)	2021-03-12	2022-09-20	주식회사 엘지에너지솔루션	버스바 어셈블리, 이러한 버스바 어셈블리를 포함하는 배터리 팩 및 이러한 배터리 팩을 포함하는 자동차
US20230114887A1 (en)	2021-10-12	2023-04-13	Lg Energy Solution, Ltd.	Battery pack and vehicle including the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5254541A (en)	1991-11-15	1993-10-19	Merck Frosst Canada, Inc.	(Quinolin-2-ylmethoxy)indole/cyclodextrin complex
CN1154070A (zh) *	1994-05-27	1997-07-09	荷兰发马克有限公司	药物组合物
EP1243582A4 (fr)	1999-12-24	2003-06-04	Kirin Brewery	Quinoline, derives de la quinazoline et medicaments contenant ces substances
KR100600550B1 (ko)	2000-10-20	2006-07-13	에자이 가부시키가이샤	질소 함유 방향환 유도체
CA2454538A1 (fr)	2001-06-22	2003-01-03	Kirin Beer Kabushiki Kaisha	Derives de la quinoleine et de la quinozoline pouvant inhiber l'auto- phosphorylation des recepteurs du facteur de croissance des hepatocytes, et composition pharmaceutique ainsi constituee
SE520606C2 (sv)	2001-06-26	2003-07-29	Flir Systems Ab	Förfarande för att åstadkomma en spegelyta, samt spegel med sådan spegelyta
JP2003238592A (ja)	2001-12-13	2003-08-27	Japan Tobacco Inc	組織及び血管の再生のための医薬及びその方法
CN1448053A (zh) *	2003-04-22	2003-10-15	西安敬业生物药物科技有限公司	甲基托布津包络物农药制剂
EP2210607B1 (fr)	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer
KR100799534B1 (ko)	2004-02-27	2008-01-31	에자이 알앤드디 매니지먼트 가부시키가이샤	신규 피리딘 유도체 및 피리미딘 유도체(1)
WO2005105044A1 (fr) *	2004-04-30	2005-11-10	Ranbaxy Laboratories Limited	Procede de fabrication d'un complexe d'inclusion de sulfonylurees presentant une solubilite aqueuse amelioree
WO2005121125A1 (fr)	2004-06-09	2005-12-22	Pfizer Inc.	Composes heteroaryle a liaison ether
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
CN100448053C (zh) *	2004-08-31	2008-12-31	清华大学	含有屏蔽掩膜支撑体的有机电致发光器件及其制备方法
AU2006229343A1 (en)	2005-03-28	2006-10-05	Kirin Pharma Kabushiki Kaisha	Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
WO2006108059A1 (fr)	2005-04-06	2006-10-12	Exelixis, Inc.	Modulateurs c-met modulators et procedes d’utilisation
US7728017B2 (en)	2005-11-30	2010-06-01	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Met and uses thereof
EP2215085B1 (fr)	2007-10-25	2011-09-07	AstraZeneca AB	Dérivés de pyridine et de pyrazine utiles pour le traitement de troubles de la prolifération cellulaire
CN101491240A (zh) *	2008-01-25	2009-07-29	国家农产品保鲜工程技术研究中心（天津）	提高纳他霉素作用效率的方法
WO2009096377A1 (fr)	2008-01-29	2009-08-06	Eisai R & D Management Co., Ltd.	Utilisation combinée d'un inhibiteur de l'angiogenèse et d'un taxane
SG188802A1 (en)	2008-03-06	2013-04-30	Genentech Inc	Combination therapy with c-met and egfr antagonists
JP4667537B2 (ja)	2008-04-10	2011-04-13	大鵬薬品工業株式会社	アシルチオウレア化合物又はその塩、及びその用途
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009140549A1 (fr)	2008-05-14	2009-11-19	Amgen Inc.	Combinaisons d'inhibiteurs de vegf(r) et d'inhibiteurs du facteur de croissance d'hépatocyte (c-met) pour le traitement du cancer
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
BR122020021551B1 (pt) *	2008-11-15	2021-09-21	Melinta Subsidiary Corp	Composição farmacêutica antimicrobiana e seu uso
CA2752232C (fr)	2009-02-12	2016-11-22	Arqule, Inc.	Composition comprenant (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione en combinaison avec un deuxieme agent anti-proliferatif
CN101926808A (zh) *	2009-06-25	2010-12-29	积华药业有限公司	氨基葡萄糖制剂
MX2012008898A (es)	2010-02-03	2012-11-06	Incyte Corp	Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
JP5960688B2 (ja)	2010-05-17	2016-08-02	インコゼンセラピューティクスプライベートリミテッド	プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
CN102274189A (zh) *	2011-07-21	2011-12-14	瑞普（天津）生物药业有限公司	一种含有癸氧喹酯的干混悬剂组方及其制备方法
CN110292575B (zh) *	2011-10-18	2022-05-13	株式会社AskAt	药物组合物
TWI594986B (zh)	2011-12-28	2017-08-11	Taiho Pharmaceutical Co Ltd	Antineoplastic agent effect enhancer
RU2494470C1 (ru)	2012-04-04	2013-09-27	Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент")	Способ лечения фиброза легких
AU2014292086B2 (en) *	2013-07-19	2019-08-08	Boehringer Ingelheim Vetmedica Gmbh	Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US9149471B2 (en)	2013-09-30	2015-10-06	National University Corporation Tokyo University Of Agriculture And Technology	Therapeutic agent for osteoporosis
EP3114144A1 (fr)	2014-03-05	2017-01-11	Bristol-Myers Squibb Company	Traitement du cancer du rein à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux
CN107427515B (zh)	2014-12-03	2021-11-16	奥克兰联合服务有限公司	用于治疗癌症的激酶抑制剂前药
KR20240064733A (ko)	2015-03-04	2024-05-13	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP2016196411A (ja)	2015-03-04	2016-11-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
WO2016175305A1 (fr) *	2015-04-30	2016-11-03	大鵬薬品工業株式会社	Sel d'acide mésylique de composé d'acylthiourée, cristaux de lui-ci, et procédés pour le produire
BR112017028137B1 (pt)	2015-06-25	2023-04-04	Taiho Pharmaceutical Co., Ltd	Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste
JP6804832B2 (ja)	2015-07-21	2020-12-23	東芝ライフスタイル株式会社	冷蔵庫
CN106551911A (zh) *	2015-09-21	2017-04-05	天津市汉康医药生物技术有限公司	一种稳定的乐伐替尼药物组合物及其制备方法
DK3583943T3 (da)	2017-02-15	2024-10-14	Taiho Pharmaceutical Co Ltd	Farmaceutisk sammensætning

2018
- 2018-02-14 DK DK18755023.1T patent/DK3583943T3/da active
- 2018-02-14 CA CA3053739A patent/CA3053739C/fr active Active
- 2018-02-14 TW TW107105612A patent/TWI702951B/zh active
- 2018-02-14 AU AU2018222163A patent/AU2018222163C1/en active Active
- 2018-02-14 MY MYPI2019004652A patent/MY194278A/en unknown
- 2018-02-14 CN CN202311298292.7A patent/CN117137915A/zh active Pending
- 2018-02-14 US US16/485,971 patent/US11110062B2/en active Active
- 2018-02-14 MA MA047516A patent/MA47516A/fr unknown
- 2018-02-14 WO PCT/JP2018/005140 patent/WO2018151177A1/fr not_active Ceased
- 2018-02-14 HU HUE18755023A patent/HUE068810T2/hu unknown
- 2018-02-14 ES ES18755023T patent/ES2991062T3/es active Active
- 2018-02-14 JP JP2018568583A patent/JP6771594B2/ja active Active
- 2018-02-14 MX MX2021007061A patent/MX2021007061A/es unknown
- 2018-02-14 PT PT187550231T patent/PT3583943T/pt unknown
- 2018-02-14 EP EP18755023.1A patent/EP3583943B1/fr active Active
- 2018-02-14 FI FIEP18755023.1T patent/FI3583943T3/fi active
- 2018-02-14 SG SG11201907433TA patent/SG11201907433TA/en unknown
- 2018-02-14 MX MX2019009717A patent/MX383728B/es unknown
- 2018-02-14 KR KR1020217035697A patent/KR20210135354A/ko not_active Ceased
- 2018-02-14 CN CN201880012000.XA patent/CN110312511B/zh active Active
- 2018-02-14 KR KR1020197023592A patent/KR102323255B1/ko active Active
- 2018-02-14 PL PL18755023.1T patent/PL3583943T3/pl unknown
2019
- 2019-08-13 PH PH12019501873A patent/PH12019501873A1/en unknown
2021
- 2021-06-15 US US17/347,989 patent/US12144892B2/en active Active

Also Published As

Publication number	Publication date
KR20210135354A (ko)	2021-11-12
KR102323255B1 (ko)	2021-11-08
SG11201907433TA (en)	2019-09-27
KR20190113831A (ko)	2019-10-08
US12144892B2 (en)	2024-11-19
CA3053739C (fr)	2023-02-14
JP6771594B2 (ja)	2020-10-21
EP3583943B1 (fr)	2024-09-18
FI3583943T3 (fi)	2024-10-29
MX2021007061A (es)	2022-10-07
PT3583943T (pt)	2024-10-15
RU2019125612A (ru)	2021-03-16
DK3583943T3 (da)	2024-10-14
TWI702951B (zh)	2020-09-01
EP3583943A1 (fr)	2019-12-25
HUE068810T2 (hu)	2025-01-28
CN110312511A (zh)	2019-10-08
AU2018222163B2 (en)	2021-01-28
BR112019016764A2 (pt)	2020-03-31
US11110062B2 (en)	2021-09-07
WO2018151177A1 (fr)	2018-08-23
EP3583943A4 (fr)	2020-12-30
MX2019009717A (es)	2019-10-02
MX383728B (es)	2025-03-14
MY194278A (en)	2022-11-25
ES2991062T3 (es)	2024-12-02
US20200060973A1 (en)	2020-02-27
PL3583943T3 (pl)	2024-11-25
PH12019501873A1 (en)	2020-06-15
US20210308056A1 (en)	2021-10-07
AU2018222163C1 (en)	2021-08-12
CA3053739A1 (fr)	2018-08-23
JPWO2018151177A1 (ja)	2019-11-07
CN110312511B (zh)	2023-10-27
CN117137915A (zh)	2023-12-01
AU2018222163A1 (en)	2019-09-05
RU2019125612A3 (fr)	2021-03-16
TW201836608A (zh)	2018-10-16

Publication	Publication Date	Title
EP3493799A4 (fr)	2020-04-01	Composition pharmaceutique decannabis
EP3493798A4 (fr)	2020-05-06	Composition pharmaceutique decannabis
KR102281667B9 (ko)	2024-01-08	아트로핀 약학 조성물 (atropine pharmaceutical compositions)
DK3529248T3 (da)	2020-09-14	Farmaceutiske sammensætninger
DK3655038T3 (da)	2025-02-17	Farmaceutisk sammensætning
EP3513809A4 (fr)	2020-06-03	Composition médicinale
MA47816A (fr)	2020-01-15	Composition pharmaceutique comprenant du sélexipag
DK3532029T3 (da)	2021-06-07	Flydende farmaceutisk sammensætning
EP3452075A4 (fr)	2019-12-11	Composition pharmaceutique ophtalmique
MA43705A (fr)	2018-11-28	Formulation pharmaceutique
DK3672631T3 (da)	2023-07-03	Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
DK3634377T3 (da)	2021-08-30	Farmaceutisk formulering
EP3603642A4 (fr)	2020-09-02	Préparation pharmaceutique
EP3402470A4 (fr)	2019-11-13	Composition pharmaceutique stable
DK3583943T3 (da)	2024-10-14	Farmaceutisk sammensætning
EP3383371A4 (fr)	2019-07-24	Formulation pharmaceutique
EP3459369A4 (fr)	2019-12-11	Composition pharmaceutique utilisant la souchelactobacillus
MA49837A (fr)	2020-06-17	Compositions pharmaceutiques
EP3582759A4 (fr)	2021-01-06	Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
EP3646863A4 (fr)	2021-03-24	Composition pharmaceutique
EP3646867A4 (fr)	2021-03-24	Composition pharmaceutique
DK3728220T3 (da)	2022-02-07	Farmaceutiske forbindelser
EP3705122A4 (fr)	2021-12-22	Composition pharmaceutique à libération prolongée
EP3524250A4 (fr)	2020-05-20	Composition pharmaceutique
MA45126A (fr)	2021-04-14	Formulation pharmaceutique antifongique